With the industry moving toward the adoption of low Global Warming Potential (GWP) propellants, pMDI developers must navigate a range of technical, regulatory and supply chain challenges. In this article for Drug Development & Delivery, Richard Turner and Simon Gardner examine the key considerations involved in enabling the shift, from selecting and safely handling next-generation propellants to ensuring product performance and clinical readiness. Read on to learn how, as the specialist CDMO, our infrastructure, partnerships, and expertise can help accelerate the delivery of low carbon inhalers to market.
Industry challenges in low carbon pMDI manufacturing
pMDI Sustainability
resource : Article
